SNAI2, a potential crossing point between cancer and cardiovascular disease

The FASEB Journal, Journal Year: 2025, Volume and Issue: 39(5)

Published: March 9, 2025

Cancer and cardiovascular disease remain the leading causes of morbidity mortality worldwide, two separate entities share several similarities possible interactions. Patients with cancer may have underlying disease, which is often exacerbated by stress tumor growth or treatment. At same time, cardiotoxicity induced anti-cancer therapies malignant process itself can lead to new diseases. Efforts been made find a rational explanation for this phenomenon. As classical tumor-promoting factor, we notice that SNAI2 simultaneously plays an important pathogenic role in Moreover, there are striking parallels mechanisms CVD, such as shared risk factors (e.g., smoking diabetes), cellular phenotypic switching, metabolic remodeling, all mediated SNAI2. This review aims summarize SNAI2's core linking well explore therapeutic approaches targeting also seeks provide insights into common both CVD.

Language: Английский

---

MMP3 as a new target of Danshensu/tetramethylpyrazine derivative for attenuating cardiac fibrosis post-myocardial infarction

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123570 - 123570

Published: March 1, 2025

Language: Английский

---

Akt mitigates ER stress-instigated cardiac dysfunction via regulation of ferroptosis and mitochondrial integrity in a DHODH-dependent manner

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123591 - 123591

Published: March 1, 2025

Language: Английский

---

Research Progress of Triptolide Against Fibrosis

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 3255 - 3266

Published: July 1, 2024

Fibrosis leads to organ failure and death, which is the final stage of many chronic diseases. Triptolide (TPL) a terpenoid extracted from traditional Chinese medicine

Language: Английский

---